Regeneron Pharmaceuticals, Inc.

In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 1, 2025), Regeneron Pharmaceuticals, Inc. reported 4 stock positions worth $1.5 billion. Its top holding was Alnylam Pharmaceuticals (ALNY) at 97.6% of the portfolio, followed by Intellia Therapeutics (NTLA, 2.3%) and Adicet Bio (ACET, 0.0%). Compared with Q1 2025, it sold out of 2. The biggest sale was an exit from 2SEVENTY Bio (TSVT).

Most Recent 13F
Q2 2026
Location
TARRYTOWN, NY
CIK
0000872589
Portfolio Value
$1.5B (Q2 2025)
SEC Filing
0001104659-25-073115 ↗ filed Aug 1, 2025

Holdings Value

0$500.0M$1.0B$1.5B Q4 2024: $1.1B Q4 2024 Q1 2025: $1.2B Q1 2025 Q2 2025: $1.5B $1.5B Q2 2025 Q3 2025: $700.4M Q3 2025 Q4 2025: $33.8M Q4 2025 Q1 2026: $47.9M Q1 2026 Q2 2026: $177.2M Q2 2026

Holdings 4 stocks · $1.5B
ALNY Alnylam Pharmaceuticals Inc. 97.59% 4,444,445 $1.4B No change
NTLA Intellia Therapeutics Inc. 2.34% 3,702,995 $34.7M No change
ACET Adicet Bio Inc. 0.04% 968,183 $591K No change
ADVM Adverum Biotechnologies Inc. 0.03% 180,909 $389K No change

Portfolio Sells Q1 2025 → Q2 2025
TSVT 2SEVENTY Bio Inc. Sold out 0.00% −0.50
BLUEBIRD BIO INC Sold out 0.00% −0.01

Portfolio Buys Q1 2025 → Q2 2025
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 3$177.2MPBLS, NTLA, ACET
Q1 2026 2$47.9MNTLA, ACET
Q4 2025 2$33.8MNTLA, ACET
Q3 2025 4$700.4MALNY, NTLA, ADVM, ACET
Q2 2025 4$1.5BALNY, NTLA, ACET, ADVM
Q1 2025 6$1.2BALNY, NTLA, TSVT, ADVM, ACET
Q4 2024 6$1.1BALNY, NTLA, TSVT, ACET, ADVM